Last reviewed · How we verify
Rituximab plus CHOP
Rituximab plus CHOP is a Monoclonal antibody and chemotherapy regimen Small molecule drug developed by Sinocelltech Ltd.. It is currently in Phase 3 development for Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.
Rituximab targets CD20 on B cells, while CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is a chemotherapy regimen.
Rituximab is an antibody that binds to the B-lymphocyte antigen CD20. It is used in combination with CHOP (a chemotherapy regimen) for the treatment of conditions such as Diffuse Large B Cell Lymphoma, Non-Hodgkin's Lymphoma, and Primary Extranodal Lymphoma.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Rituximab plus CHOP |
|---|---|
| Sponsor | Sinocelltech Ltd. |
| Drug class | Monoclonal antibody and chemotherapy regimen |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion. CHOP is a combination chemotherapy regimen that targets rapidly dividing cells, including cancer cells.
Approved indications
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Infection
- Fatigue
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (PHASE2)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (PHASE3)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (PHASE2)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab plus CHOP CI brief — competitive landscape report
- Rituximab plus CHOP updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI
Frequently asked questions about Rituximab plus CHOP
What is Rituximab plus CHOP?
How does Rituximab plus CHOP work?
What is Rituximab plus CHOP used for?
Who makes Rituximab plus CHOP?
What drug class is Rituximab plus CHOP in?
What development phase is Rituximab plus CHOP in?
What are the side effects of Rituximab plus CHOP?
What does Rituximab plus CHOP target?
Related
- Drug class: All Monoclonal antibody and chemotherapy regimen drugs
- Target: All drugs targeting CD20
- Manufacturer: Sinocelltech Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-Hodgkin's lymphoma
- Indication: Drugs for Chronic lymphocytic leukemia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing